Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Aligning, Appraising, and Simplifying Scientific Data Strengthens Promotional Claims

Pharmaceutical companies must convert complex scientific data into clear promotional materials that comply with regulatory standards and effectively communicate with healthcare professionals and patients. This involves evaluating data alignment, assessing evidence quality, and simplifying messaging. Missteps can result in legal and financial repercussions.

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Vodori on MarketScale.

By Annalise Ludtke ·
Share
Aligning, Appraising, and Simplifying Scientific Data Strengthens Promotional Claims

Key takeaways

01

Evaluate new scientific data for alignment with drug's indication and regulatory constraints.

02

Thorough appraisal of evidence quality is crucial for credible claims.

03

Clear communication requires simplifying complex data while maintaining accuracy.

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

The pharmaceutical industry faces the challenge of converting complex medical and scientific information into clear, effective promotional claims. This process is critical as it balances the need for accurate scientific communication with the requirement for impactful marketing. The stakes are high, as promotional materials must adhere to stringent regulatory standards while also appealing to healthcare professionals and patients. Missteps can lead to significant legal and financial repercussions, making it essential for pharmaceutical companies to get this process right.

Missteps can lead to significant legal and financial repercussions, making it essential for pharmaceutical companies to get this process right.

How do teams navigate the complexities of transforming dense scientific data into clear, approvable promotional material without losing accuracy or impact?

On this episode of Amend & Progress, hosted by Annalise Ludtke, Joe DiCapite, Director of Strategy for the UK and Europe at Vodori, delves into the intricate process of converting medical and scientific information into claims. Together, they discuss the challenges, best practices, and the importance of inter-team collaboration in ensuring successful outcomes.

Key Discussion Points

  • Ensure appropriateness: Teams must first evaluate whether new scientific data aligns with their drug's indication and regulatory constraints to determine its suitability for promotional claims.
  • Assess evidence quality: A thorough appraisal of the evidence's quality, including study design and statistical significance, is crucial to ensure the claim's credibility and withstand scrutiny from competitors and regulators.
  • Effective communication: Transforming complex scientific data into clear, impactful, and accurate claims requires simplifying jargon while maintaining precision, tailored to different audience needs, and considering the overall impression of the promotional material.

Joe DiCapite brings extensive experience in medical writing, medical affairs, and marketing. His background includes a strong foundation in the pharmaceutical industry, with a focus on critical appraisal and compliance processes. His expertise spans both the strategic and operational aspects of converting scientific data into promotional claims, making him a valuable voice in this field.

Vodori

Part of this channel

Vodori

Faster market access through compliant life science content review.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

AL
Annalise Ludtke

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

Value-based care reaches a quarter of revenue at 30% of surveyed health organizations

Value-based care reaches a quarter of revenue at 30% of surveyed health organizations

Wolters Kluwer Health argues value-based care software is judged on whether customers hit incentive thresholds and avoid penalties. A Fierce Healthcare-reported survey it cites puts value-based care at a quarter or more of revenue for 30% of organizations. The analysis is a vendor publication that ends by pitching its own UpToDate Connect API.

  • 01The sharper question for any population health or care coordination platform is whether it changes what a clinician does at the moment of decision, or only reports afterward what happened. Wolters Kluwer's reading of the evidence is that many platforms still struggle with the first.
  • 02Vendors selling into value-based contracts now face a build-or-license decision on clinical content, because Wolters Kluwer names current, trusted content, consistent clinician adoption across sites, and a traceable link from guidance to quality metrics as the three hard problems.

Sep 18, 2026

Hospitals lost money on telehealth with every payer type in 2025

Strata Decision Technology's Performance Trends report found telehealth encounters at U.S. hospitals rose 79% from January 2019 to January 2026, yet average total cost margins were negative for commercial, Medicare, Medicaid and self-pay patients in 2025. Adoption has outrun reimbursement. The gap lands on health systems that posted a 0.2% operating margin in April, according to Strata.

  • 01A negative total cost margin on telehealth across all four payer categories is now a national benchmark from a dataset covering more than 2,200 hospitals; a health system's own per-encounter virtual care margin can be measured against it.
  • 02Remote patient monitoring encounters grew nearly 4,000% since 2019 while reimbursement for the service is still maturing, so an RPM business case built on volume alone will miss the number that actually decides its viability.
  • 03The signal to watch is whether any single payer category shows a positive telehealth margin in Strata's next Performance Trends cut. As of the 2025 data, none did.

Sep 18, 2026

Most reprocessing audit gaps trace back to training, turnover and leadership

Most reprocessing audit gaps trace back to training, turnover and leadership

Joint Commission findings on its reprocessing standard point mostly to training, turnover, leadership and missing ownership, not sterilizers. CDC epidemiologists and a 2019 review add cleaning verification and manufacturer instructions as the steps to watch. Audit people and process steps as closely as the autoclave.

  • 01Of the Joint Commission's list of reasons hospitals miss reprocessing standard IC.02.02.01, at least eight concern people, priorities and management, so competency records and a named process owner belong in the audit as much as sterilizer logs.
  • 02A structured audit tool that scores compliance step by step, as a 2020 BMC Health Services Research study did across 189 reprocessing cycles, shows where training hours should go; the Nepal hospitals scored best on cleaning and storage and worse on the steps between.

Sep 14, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

About the Experts

JD
Joe DiCapite

Director of Strategy for the UK and Europe

Vodori

Joe DiCapite brings extensive experience in medical writing, medical affairs, and marketing. His background includes a strong foundation in the pharmaceutical industry, with a focus on critical appraisal and compliance processes. His expertise spans both the strategic and operational aspects of converting scientific data into promotional claims.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512